Live Breaking News & Updates on Nephrol hypertens

Stay informed with the latest breaking news from Nephrol hypertens on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nephrol hypertens and stay connected to the pulse of your community

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Greenwich , United-kingdom , J-clin-hypertens , Clin-pharmacokinet , Nephrol-hypertens , Dial-transplant , Practice-guideline , Diabetes-management , Chronic-kidney-disease , Chronic-kidney-dis , Clin-hypertens

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Radnor , Pennsylvania , United-states , Philadelphia , American , Catalys-pacific , Nephrol-hypertens , Tanabe-pharma , Tom-weible , David-rodman , Nasdaq , Exchange-commission

Fluid retention and heart failure in the PRECISION trial

Fluid retention and heart failure in the PRECISION trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Markusp-schlaich , Eli-lilly , Nephrol-hypertens , Astrazeneca , Novartis , Travere-pharmaceuticals , Elsevier-ltd , Boehringer-ingelheim , Opin-nephrol-hypertens , Travere-therapeutics , Chinook-therapeutics ,

Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial

In adult kidney transplant recipients, correction of metabolic acidosis by treatment
with sodium bicarbonate over 2 years did not affect the decline in estimated GFR.
Thus, treatment with sodium bicarbonate should not be generally recommended to preserve
estimated GFR (a surrogate marker for graft function) in kidney transplant recipients
with chronic kidney disease who have metabolic acidosis.

United-kingdom , Switzerland , London , City-of , British , Semin-nephrol , Nephrol-hypertens , Clin-nephrol , National-institute-for-health , Work-group , Kidney-blood-press-res , Summary-of-the-british-transplantation-society-guidelines

Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G

Posted December 16th, 2020 for Novartis
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life
1–3
C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need
4-5
With potential to be the first oral treatment for a range of complement-driven diseases, complement factor B inhibitor iptacopan targets the underlying cause of these conditions through its action on the complement system’s alternative pathway
6,7
Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgA nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and membranous nephropathy (MN); first FDA filings anticipated in 2023

United-states , America , American , Eric-althoff , Isabella-zinck , Samir-shah , Thomas-hungerbuehler , Phil-mcnamara , Sloan-simpson , Nephrol-hypertens , Twitter , Drug-administration